Exons 5, 7, 8 and 9 were reported to share a better prognosis than other sites (26); it is worth mentioning that the study referred here sought to reveal the prognostic value of TP53 alterations in advanced NSCLC compared to most of studies limited to the early stage or EGFR-mutant background (30, 31). This evidence concerns the gene EGFR and non-small cell lung carcinoma.